Cabozantinib Could Inhibit Hepatitis A Virus Replication in Human Hepatoma Cell Lines
Year: 2026
Type: article
Abstract: Background/Objectives: Tyrosine kinase inhibitors (TKIs) have been reported to suppress the replication of several hepatotropic viruses. Despite being preventable through vaccination, hepatitis A virus (HAV) infection is still a worldwide public health issue and is also prevalent in Japan. In the context of Japan’s aging population, it is expected that the number of patients with severe hepatitis A will increase. Therefore, it is important to develop antiviral agents against HAV as therapeutic options for severe hepatitis A. Methods: In the present study, the effects of several anticancer drugs on HAV replication were examined in human hepatoma cell lines, including TKIs, which are currently used to treat patients with hepatocellular carcinoma. Results: A 48 h treatment of cabozantinib effectively inhibited HAV HA11-1299 genotype IIIA replication, and a 24 h treatment of cabozantinib with an IC50 of 3.1 µM inhibited replication of the HAV HM175-18f genotype IB subgenomic replicon. Conclusions: Cabozantinib could inhibit HAV replication in vitro and may be useful for the drug development for HAV infection.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm15229081
Authors: Tatsuo Kanda(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review & editing), Reina Sasaki-Tanaka(Conceptualization, Funding acquisition, Project administration, Resources, Writing – review & editing), Hiroyuki Abe(Writing – review & editing), Takeshi Yokoo(Writing – review & editing), Akira Sakamaki(Writing – review & editing), Kazunao Hayashi(Writing – review & editing), Hiroteru Kamimura(Writing – review & editing), Hiroaki Okamoto(Funding acquisition, Supervision), Shuji Terai(Funding acquisition, Supervision)
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7236833074
